Loading

mCRPC

Androgen Receptor Gene Alterations and mCRPC Treatment Outcomes

Investigators assessed the impact of androgen receptor (AR) gene alterations in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line treatment with AR-targeted agents (ARATs). Lead author of the study, Nishita Tripathi, reported that patients with mCRPC who had AR alterations in circulating tumor DNA (ctDNA) had worse outcomes compared with patients with wild-type AR status. The data were presented at the ESMO Congress 2022. ...

Advertisement

Latest News

Advertisement

Prostate Cancer Knowledge Hubs

Curated clinical content on prostate cancer types, therapies, and technologies

Prostate Cancer
Prostate Cancer

Conference Coverage

Advertisement
Advertisement
Trending

Patrick Daly

Advanced Urothelial Carcinoma | March 21, 2022

Metabolites were shown to have “the highest potential for differences between urine levels in healthy and BC patients."

Patrick Daly

Advanced Urothelial Carcinoma | March 21, 2022

Smoking increased risk of urothelial carcinoma “more than expected” in patients with certain genetic risk factors.

Patrick Daly

Advanced Urothelial Carcinoma | March 21, 2022

Researchers developed a model to predict bladder cancer recurrence by combining microRNA with a pathological factor.